Understanding Fabry Disease: A Resource Hub for Healthcare Professionals

Fabry disease presents with diverse symptoms, including neuropathic pain, angiokeratomas, hypohidrosis, gastrointestinal discomfort, renal dysfunction, and cardiovascular complications. Symptoms vary in severity and may be misattributed to more common conditions.

Diagnosing Fabry disease can be challenging due to its rarity, variable presentation, and overlap with other conditions. Genetic testing and awareness of red-flag symptoms are critical for timely diagnosis.

Fabry disease affects multiple systems, including the cardiovascular, renal, neurological, and gastrointestinal systems, through the accumulation of globotriaosylceramide (Gb3) in cells, leading to progressive damage over time.

Management guidelines emphasise early diagnosis, initiation of enzyme replacement therapy or chaperone therapy, regular monitoring of organ function, and multidisciplinary care to address complications.

At-risk patients include those with unexplained left ventricular hypertrophy, stroke at a young age, renal dysfunction, or a family history of Fabry disease. Screening and genetic testing are key.

Fabry disease can cause left ventricular hypertrophy, arrhythmias, valve dysfunction, and heart failure due to Gb3 accumulation in myocardial cells and vascular endothelial cells.

Cardiac MRI with late gadolinium enhancement and echocardiography are valuable tools for identifying characteristic features of Fabry cardiomyopathy, such as left ventricular hypertrophy and fibrosis.

Left ventricular hypertrophy in Fabry disease often presents with symmetrical thickening and may be accompanied by diastolic dysfunction and arrhythmias, which can mimic hypertrophic cardiomyopathy.

Patients with Fabry disease may experience abdominal pain, diarrhoea, bloating, and nausea, often resulting from Gb3 accumulation in the gastrointestinal tract and autonomic nervous system.

Symptoms from irritable bowel syndrome, inflammatory bowel disease, or functional dyspepsia can overlap with Fabry-related gastrointestinal issues, leading to misdiagnosis without genetic testing.

Enzyme replacement therapy can reduce Gb3 accumulation and improve gastrointestinal symptoms in patients with Fabry disease, contributing to overall quality of life.

GPs play a vital role in identifying early signs, initiating genetic testing, and coordinating care with specialists to manage Fabry disease and its complications effectively.

Referral is recommended for patients with red-flag symptoms (e.g., unexplained kidney issues, cardiac symptoms, or neuropathic pain) or a positive family history of Fabry disease.

Red flags include unexplained pain, proteinuria, premature stroke, left ventricular hypertrophy, cornea verticillata, and a family history of Fabry disease.

Fabry disease is caused by mutations in the GLA gene, which encodes the enzyme alpha-galactosidase A. Over 1,000 pathological mutations have been identified, with varying clinical implications.

Fabry disease follows X-linked inheritance. While males often experience more severe symptoms, females can also develop significant manifestations due to random X-chromosome inactivation.

Genetic counselling helps families understand the inheritance pattern, assess the risk for relatives, and facilitate early diagnosis and intervention.

Gb3 accumulation in renal cells causes glomerular, tubular, and vascular damage, leading to proteinuria, reduced glomerular filtration rate, and eventually end-stage kidney disease.

Key biomarkers include proteinuria, reduced alpha-galactosidase A enzyme activity, elevated plasma lyso-Gb3 levels, and evidence of Gb3 accumulation on kidney biopsy.

Enzyme replacement therapy and chaperone therapy slow renal progression, while adjunct treatments like ACE inhibitors or ARBs manage proteinuria and hypertension.

Neurological symptoms include burning pain in hands and feet (acroparesthesia), dizziness, headaches, and increased risk of stroke or transient ischemic attacks at a young age.

Fabry disease causes small vessel disease due to Gb3 deposition in cerebral blood vessels, increasing the risk of ischemic strokes, particularly in younger patients.

Neurologists can use nerve conduction studies, quantitative sensory testing, and assessment of lyso-Gb3 levels to diagnose and monitor Fabry-related neuropathy.

Cornea verticillata (whorled opacity) is a hallmark feature. Other findings include conjunctival vessel tortuosity and posterior capsular cataracts.

Cornea verticillata is easily observed during slit-lamp examination and is often an early, non-invasive indicator of Fabry disease.

Routine eye exams can help detect early signs of Fabry disease, monitor disease progression, and provide clues for systemic involvement.